CD8A and cancer: Perhaps the most successful form of anticancer immunotherapy, which is commonly known as immune checkpoint blockade, relies on monoclonal antibodies that interrupt inhibitory signals provided by cancer cells or other cells of the TME to cytotoxic CD8+ T lymphocytes, including signals elicited by PD-L124.